Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialisation of transformative therapies for patients living with central nervous system disorders with high unmet medical needs, has named Diane Wilfong as its new director, it was reported yesterday.

Wilfong has more than 30 years of financial and operations experience in large, multinational companies, including most presently serving as senior vice president, controller and chief accounting officer of Gilead Sciences Inc. Prior to joining Gilead in 2016, she was vice president, controller and principal accounting officer at Computer Sciences Corporation. From 2009 to 2014, she led the accounting and tax functions at Caesars Entertainment and spearheaded a major financial transformation initiative along with key elements of a public offering, and was responsible for Sarbanes-Oxley compliance in her role. Prior, she spent 10 years at Eastman Kodak Company in a series of executive, operational and financial roles, including serving as general manager of the company's Graphics and Printing Systems group, and later as the corporate controller and chief accounting officer. Prior to Kodak, she held positions at Corning and at Price Waterhouse.

Jon Congleton, president and chief executive officer of Impel, said, 'Impel is rapidly advancing a late-stage pipeline of therapies for CNS disorders with high unmet medical needs, all of which are the result of over a decade of pioneering a unique approach to drug delivery. We are pleased to welcome Diane to Impel's board, and we look forward to leveraging her dynamic leadership experience and extensive background in finance as we continue to grow into a fully integrated R&D and commercial organisation.'